High molecular weight kininogen deficiency (HMWKD) is a rare hereditary disorder caused by insufficient production of high molecular weight kininogen, a protein that plays a key role in the hemostasis and inflammation system. This protein activates the complement system and serotonergic transmission, which contributes to the formation of a protective reaction of the body. Clinical and laboratory manifestations will vary from mild to severe, which is associated with a high risk of thrombosis and thromboembolic complications. The lack of adequate diagnosis and treatment can lead to significant health problems and a decrease in the quality of life of patients, so timely detection of the disease and its correction is an important aspect.
History of the disease and interesting historical facts
High molecular weight kininogen deficiency was first described in the 1960s, when researchers began to identify a link between its deficiency and certain clinical manifestations in patients with bleeding disorders. Interestingly, the disease was initially considered extremely rare, but it was later found that many cases remained undiagnosed. A major milestone in the study of the disease was the discovery of a link between genetic mutations and clinical severity, which led to a deeper understanding of the pathogenesis and mechanism of action of high molecular weight kininogen. Research conducted in the 1980s and 1990s significantly expanded our knowledge of the role of this protein in the body, which allowed us to develop more effective diagnostic and treatment strategies.
Epidemiology
Globally, the prevalence of high molecular weight kininogen deficiency remains low due to its genetic nature and rarity. According to various estimates, the disease occurs with a frequency of 1 in 500,000 - 1 in 1,000,000 people. However, in some populations with high rates of consanguinity, such as some groups in the Middle East, the incidence may be higher. There is information that women affected by the disease may be less noticeable due to lesser manifestations of clinical symptoms compared to men. Given the importance of the recording and observation system, ongoing work on collecting statistical data is necessary to accurately understand the dynamics of the condition.
Genetic predisposition to this disease
High molecular weight kininogen deficiency is caused by mutations in the KLKB1 gene located on chromosome 4. Mutations can be different and are often inherited in an autosomal recessive manner. If one mutation is present, the patient may have high plasma kininogen levels, but this is not always accompanied by clinical manifestations. In this situation, it is also important to examine for possible polymorphisms in other genes, such as blood clotting factors, which can significantly affect the severity of the disease. Knowledge of predisposition can help in early diagnosis and prevention of serious complications.
Risk factors for the development of this disease
Despite the genetic nature of the unfavorable condition, there are a number of factors that can increase the risk of developing or worsening the clinical picture. These include:
- Physical factors: injuries, surgeries, increased physical activity;
- Chemical factors: use of anticoagulants, exposure to certain medications, toxic substances;
- Other diseases: previous diseases of the blood coagulation system, chronic renal failure;
- Environment: living conditions, influence of climatic factors.
An integrated approach to assessing the patient’s health status is important, namely, taking into account all factors, which will allow developing an individualized treatment strategy.
Diagnosis of this disease
Diagnosis of high molecular weight kininogen deficiency is usually made using the following methods:
- Main symptoms: tendency to bruise, increased bleeding, thrombosis;
- Laboratory tests: assessment of kininogen levels, coagulogram, tests for factor Xa activity;
- Radiological examinations: ultrasound to detect thrombus formation, CT to exclude other causes of symptoms;
- Other types of diagnostics: genetic tests to detect carriage of mutations in the KLKB1 heme;
- Differential diagnosis: exclusion of other thrombophilic diseases.
The first priority is to completely exclude other stations with similar symptoms, which is especially important for establishing the correct diagnosis and starting therapy.
Treatment
Treatment of high molecular weight kininogen deficiency must be individualized for each patient and may include different approaches:
- General treatment: lifestyle changes, reduction of physical activity during periods of exacerbation;
- Pharmacological treatment: administration of anticoagulants to prevent thrombus formation;
- Surgical treatment: In rare cases, surgery may be required to remove the blood clot;
- Other treatments include genetic counseling to identify risks in offspring.
Correction of the condition in most cases can be achieved with the help of conservative therapy, but in complex cases more radical measures will be required.
List of medications used to treat this disease
Among the drugs that can be used to treat high molecular weight kininogen deficiency are:
- Anticoagulants (eg, warfarin);
- Direct anticoagulants (dabigatran);
- Fibrinolytics in case of thrombosis (streptokinase);
- Biopharmaceuticals aimed at improving kininogen levels.
The choice of a specific type of treatment depends on the clinical situation and is determined by the attending physician individually.
Disease monitoring
Monitoring of the patient's condition with high molecular weight kininogen deficiency includes regular clinical and laboratory examinations:
- Control stages: monitoring the level of kininogen, coagulogram, ultrasound of the veins for thrombus formation;
- Prognosis: if all recommendations are followed and proper treatment is administered, the prognosis is generally favorable;
- Complications: thrombus formation, pulmonary embolism.
Timely research and treatment adjustments can significantly improve the quality of life of patients.
Age-related features of the disease
High molecular weight kininogen deficiency can occur in different age groups:
- In newborns: asymptomatic course is possible;
- In children: mild forms are often detected, which may resolve spontaneously;
- In adults: more pronounced thrombus formation and clinical manifestations;
- In the elderly: the risk of thrombosis increases significantly against the background of other diseases.
Age-related changes in the body can also affect the course and severity of symptoms, which requires an individual approach to each patient.
Questions and Answers
- What are the main symptoms of high molecular weight kininogen deficiency? The main symptoms are a tendency to bruise, prolonged bleeding during and after injuries, and the appearance of blood clots.
- How to diagnose high molecular weight kininogen deficiency? Diagnosis is based on clinical manifestations, laboratory tests for kininogen levels and genetic studies.
- Is it possible to prevent blood clots in this disease? Yes, the use of anticoagulant therapy can significantly reduce the risk of blood clots.
- What is the treatment for high molecular weight kininogen deficiency? Treatment includes pharmacological therapy aimed at preventing thrombus formation, and possibly surgical intervention in severe cases.
- What is the prognosis for this disease? With adequate therapy and adherence to doctors' recommendations, the prognosis is favorable in most cases.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov notes that if you have symptoms characteristic of a deficiency of high molecular weight kininogen, you should immediately consult a doctor. He also recommends:
- Undergo regular medical examinations and laboratory tests to monitor your condition;
- Monitor changes in your health and notify your doctor if you experience new symptoms;
- Discuss any changes in treatment with your healthcare professional to avoid complications.
Thus, by conducting timely diagnostics and starting adequate treatment, patients have every chance of successfully managing their condition and improving their quality of life.
